Nestlé Health Science and Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that they have signed an agreement in which Nestlé Health Science will acquire the VOWST business.
Nestlé Health Science has been commercializing the VOWST (fecal microbiota spores, live-brpk) capsules since its launch in June 2023 in the United States. This transaction will allow Nestlé Health Science full control over the further development, commercialization, and manufacturing of VOWST in the US and worldwide.
“VOWST is a first of its kind, and we have been extremely pleased with its success over the past 14 months,” said Moreno Perugini, President of Medical Nutrition and Pharma, Nestlé Health Science. “With this transaction, we will further grow the business to make this medication available to more patients.”
VOWST is the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic to prevent recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI).
The transaction is subject to Seres shareholder approval. Closing is anticipated within 90 days.
